微创肺表面活性物质给药在≤30周早产儿呼吸窘迫综合征中的疗效:多中心随机对照试验
该多中心前瞻性随机对照试验纳入92例胎龄≤30周诊断NRDS的早产儿,比较微创给药(MISA)与气管插管给药(EISA)牛肺磷脂70~100 mg/kg的可行性与安全性。结果显示MISA组注药时间和总操作时间更长,但hsPDA和BPD发生率更低。
要点
- MISA适用于胎龄≤30周NRDS早产儿,操作可行且无不良影响。
- MISA组注药时间和总操作时间显著长于EISA组。
- MISA组hsPDA和BPD发生率低于EISA组。
核心结论
- 微创应用肺表面活性物质适用于出生胎龄≤30周的NRDS早产儿,虽操作时间更长,但可降低hsPDA和BPD发生率。
研究设计与样本
- 多中心前瞻性随机对照研究,纳入2017年7月1日至2018年12月31日京津冀地区8家三级医院NICU出生胎龄≤30周考虑NRDS的患儿92例,按计算机随机分为MISA组47例和EISA组45例。
主要发现
- MISA组注药时间60(18,270)s长于EISA组50(30,60)s(Z=3.009,P=0.003)。
- MISA组总操作时间90(60,300)s长于EISA组60(44,270)s(Z=3.365,P=0.001)。
- MISA组hsPDA发生率36%(17/47)低于EISA组67%(30/45)(χ²=8.556,P=0.003)。
- MISA组BPD发生率26%(12/47)低于EISA组47%(21/45)(χ²=4.464,P=0.035)。
关键数值与推荐
- 两组均给予牛肺磷脂70~100 mg/kg。
- MISA组通过胃管给药,EISA组通过气管插管给药。
临床怎么用
- 对胎龄≤30周NRDS早产儿可考虑采用MISA给药,需接受操作时间较EISA更长。
- MISA可能降低hsPDA和BPD发生率,但需结合患儿具体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the feasibility and safety of minimally invasive surfactant administration (MISA) in preterm neonates with respiratory distress syndrome (NRDS). Methods: In this multicenter prospective randomized controlled trial, 92 preterm infants with gestation age ≤30 weeks and diagnosed with NRDS were enrolled in 8 level Ⅲ neonatal intensive care units (NICU) in Beijing-Tianjin-Hebei Region from 1(st) July 2017 to 31(st) December 2018. They were randomly assigned to minimally invasive surfactant administration (MISA) group or endotracheal intubation surfactant administration (EISA) group according to random number generated by computer. Infants in both groups received calf pulmonary surfactant preparation at a dose of 70-100 mg/kg. The data of demography, perinatal situation, medication administration, complications, clinical outcomes in the two groups were compared with Chi-square test, Student's t-test, Mann-Whitney U test or Fisher's exact test. Results: Among the 92 preterm infants, 53 were males, 39 were females; 47 were in the MISA group (25 males), and 45 were in the EISA group (28 males). The gestational age and birth weight were (29.5±1.2) weeks and (1 271±242) g in all patients, (29.5±1.4) weeks and (1 285±256) g in the MISA group, and (29.6±0.9) weeks and (1 255±227) g in the EISA group. The duration of surfactant infusion and the length of whole procedure in the MISA group were significantly longer than that in the EISA group (60 (18, 270) s vs. 50 (30, 60) s, Z=3.009, P=0.003; 90 (60, 300) s vs. 60 (44, 270) s, Z=3.365, P=0.001). For the outcomes, the incidence of hemodynamically significant patent ductus arteriosus (hsPDA) and bronchopulmonary dysplasia (BPD) were lower in the MISA group than in the EISA group (36% (17/47) vs. 67% (30/45), χ(2)=8.556, P=0.003; 26% (12/47) vs. 47% (21/45), χ(2)=4.464, P=0.035). Conclusions: Minimally invasive surfactant administration is applicable in preterm infants ≤30 weeks gestational age with NRDS. Although the length of whole procedure is longer than route endotracheal administration, the benefit of decreasing the incidences of hsPDA and BPD outweighs this demerit. 目的: 评价微创应用肺表面活性物质对早产儿呼吸窘迫综合征(NRDS)的疗效以及操作的可行性和安全性。 方法: 采用多中心前瞻性随机对照研究,以2017年7月1日至2018年12月31日京津冀地区8家三级医院新生儿重症监护病房出生胎龄≤30周考虑NRDS的患儿92例为研究对象。根据肺表面活性物质给药方式按计算机随机方法分为微创给药组和常规给药组,分别通过胃管或气管插管给予牛肺磷脂70~100 mg/kg。采用t检验、χ(2)检验、连续性校正χ(2)检验、Mann-Whitney U检验、Fisher精确检验对两组人口学信息、围生期情况、用药情况、合并症、临床转归等病例资料进行分析。 结果: 92例患儿中男53例、女39例,出生胎龄(29.5±1.2)周,出生体重(1 271±242) g。微创给药组47例,其中男25例,出生胎龄(29.5±1.4)周,出生体重(1 285±256)g;常规给药组45例,其中男28例,出生胎龄(29.6±0.9)周,出生体重(1 255±227)g。微创给药组的注药时间和总操作时间均长于常规给药组[60(18, 270)比50(30,60)s, 90(60,300)比60(44,270)s,Z=3.009、3.365,P=0.003、0.001],微创给药组的有血液动力学影响的动脉导管未闭(hsPDA)、支气管肺发育不良(BPD)发生率均低于常规给药组[36%(17/47)比67%(30/45),26%(12/47)比47%(21/45),χ(2)=8.556、4.464,P=0.003、0.035]。 结论: 微创给药技术操作适用于出生胎龄≤30周的早产儿,虽有一定难度,操作时间明显长于气管插管给药,但是技术可行且与气管插管给药比较无不良影响,可降低hsPDA、BPD的发生率。.
引用
- Liu HQ, Tong XM, Han TY, et al. [Efficacy of minimally invasive pulmonary surfactant administration in preterm infants with neonatal respiratory distress syndrome: a multicenter clinical trial]. Zhonghua Er Ke Za Zhi. 2020. PMID: 32392952. doi:10.3760/cma.j.cn112140-20191018-00658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。